


Platycodin D Improves the Immunogenicity of Newcastle Disease Virus-Based Recombinant Avian Influenza Vaccine in Mice







```
678
                                                   . 7 (2010)
                                                      60%
                                                                           (261
                                        8.
                               9.
                                  10 .
                   11,
           A 12,
                    13 16,
                              ) 17
                                                                      ) 18 21 .
                                A<sub>¬</sub>-,
23 24 . A
                                                         25 26.
(A ) 29 , -21
5 1 . A
 30,
                                                                  31 . A
                                        -21
                       ₅⊿y 33 .
               (1)
   Platycodon grandiflorum. A
  35 ,
₅₄y
                                  ( - 5)
```


Results. Effects of 1 on Splenocyte Proliferation in Mice Immunized with rL-H5.


Effects of 1 on Natural Killer (NK) Cell Activity in Mice Immunized with rL-H5.


5.
Effects of 1 on the Antigen-Specific Serum Antibody Response.

5A Fig. 3.
5A A , 1 - 5

$$(P < 0.05, P < 0.01, P < 0.001).$$
 $. 5A - 1$
 $A , 1, P < 0.001).$
 $. (P < 0.01 P < 0.001).$







```
C & B 7 7 & B 7 7 .7 (2010)
                   1.40 1.39, <sub>5,4</sub>y
                                                                             2- ₅₄y
                                                            - 5/1 (75 \mu)
                                                                             1.03
    1.01,
                                     - 5/
                                                                               0.98,
                                                                     0.95
   Effects of 1 on the mRNA Expression of Cytokines and Transcription Factors.
                                   A A-3 (7-\gamma) (7-10) , y (7able 1),
                  Table 2. A (25 \mu)
                                             1(75 \,\mu)
                                                                 A A-3 (P < 0.01
                   2 ,-y __-10
  - (P<0.01 P<0.001)
A A-3 A
(P < 0.01 \quad P < 0.001).
                                                                       (P > 0.05)
    \neg \frac{-\gamma}{-5/A} \quad . \qquad , \mathbf{1} \quad -
                                                                         - 5
                                                                         2 ₅⁴y
                                                   A A-3
                  - 5.
                      1. Sequences of the Specific Primers Used for RT-PCR
```

A)	5'-CCCACA AAA CAAC CAC-3'	570
	5'-CA A AACAC A-3'	
-γ	5'- AAC C ACACAC CA C -3'	459
	5'-C AC CC CC C A -3'	
,-10	5'-CCA ACC A AA A -3'	324
	5'- C A CC A CCA CA AC CAA-3'	
	5'AACCA A CC CCCA C-3'	436
	5'- C CCAC AA A A -3'	
A A-3	5'- AA CA CCA ACCC AAAC-3'	255
	5'-ACCCA C ACCA C-3'	

Discussion.

, Ay , Ay ,

, Ay , Ay ,

, Ay , Ay ,

, B

36 .

B

(A A)

B

(A A)

B

(A A)

B

(B A)

Ay (A A)

B

(B A)

Ay (A A)

B

(B A)

Ay (A A)

Ay (A A)

B

(B A)

Ay (A A)

Ay (A A)


B

Ay (B A)

Ay



2



. 4. Effects of Alum, Quil A, and **1** on the mRNA expression of GAPDH, cytokines, and transcription factors in splenocytes from mice immunized with rL-H5.

- ,

2. Effects of Alum, Quil A, and 1 on the mRNA Expression of Cytokines and Transcription Factors in Splenocytes from Mice Immunized with rL-H5.

(Table 1 Exper. Part).

GoldView

A

± (n 3).

	- 5	- 5 A (200 μ)	- 5 A (25 μ)	- 5 1 (75 μ)
	0.25 ± 0.01 0.42 ± 0.03 0.20 ± 0.03	0.28 ± 0.01 0.50 ± 0.09 0.57 ± 0.05 (c)	$0.56\pm0.06 (c)$) $0.72\pm0.08 (b)$ $0.57\pm0.04 (c)$	$0.50 \pm 0.01 (c)$ $0.58 \pm 0.05 (b)$ $0.42 \pm 0.03 (c)$
'A A-3	0.33 ± 0.03	0.65±0.06 (b)	$0.53 \pm 0.09 (b)$ (b) $P < 0$	$0.55 \pm 0.13 (b)$ 0.01 (c) $P < 0.001$.





National Natural Science Foundation of China (.30871888),
Zhejiang Provincial Natural Science Foundation of China (.3080027), National Key
Project of Scientific and Technical Supporting Programs Funded by Ministry of Science and Technology of
China (.2008BA B4B06-2), Administration of Traditional Chinese Medicine of
Zhejiang Province (.A2006Z017)

```
Experimental Part
                                                                                  ( - 5),
                             ( )-
5- 5- 4 (A_)
5 5- 4 A_
Harbin Weike Biotechnology Development Company (
                  General.
                                                                                 ( A) ,-y
                                                                                     , C ). 3-(4,5-
                Chemical Co. (
              lopyranosyl-(1\rightarrow 4)-\alpha\text{-L-}rhamnopyranosyl-(1\rightarrow 2)-\alpha\text{-L-}arabinopyranoside}]; \textbf{1}). \qquad \textbf{,-y} \qquad (C_{57~92~28}, \\
                              5-4¥
                                                         P. grandiflorum,
              1224.5775)
. 1(4 / ) 0.89%
                                                                     ,⊿y
                              Limulus
                              (AC)/ .
              18 22
               . 22-2001001)
                           ad libitum,
     24 \pm 1^{\circ}, 50 \pm 10\% .
                            ₅,y 12-
           - 5 (10
                                (200 \,\mu), A(25 \,\mu), \mathbf{1}(50,75, 100 \,\mu) 0.2
                                                                     2
                - 5.
Splenocyte Proliferation Assay.
Hank'
                             . (B, Sigma),
                                                                                          <sub>4</sub>C (0.8%,
                                    (380g 4° 10 ),
                                                                  12 m HEPES
                                            (RPMI 1640
                                            (\overset{)}{\cancel{100}} \neg / ),
              0.05 м 2-
                                                               -y (100 μ / ), 10% C).
                              / 100 µ
                                                              С А (
                                                                                      5 μ / ),
                               10 μ / ), 5A (
. 200 μ. A
                                                              0.125
                                                                                      ( A )/ ),
                       , 44 , 50 μ (2 , 1400g 5 , (200 μ) 570
                                                           15 4 630-
                                             570
```

C & B , , , 2010)

686

, C ;

.09% **,-**y C.

, ,y

ental Animal Center (

5**-**₹(sc)

pore

```
<sup>ζ</sup> 562
                                       Institute of Cell Biology, Chinese Academy of Sciences,
                                                      RPMI 1640
                         -⊿y
                                           (100 _ / ; Sigma),
5% C 2.
                       2 M L-
                                 (Sigma),
                                                          ,-y (100 μ / ; Sigma),
                        \mathbf{C}
                                            96-
                       1640
                                                                         1 \times 10^6
                                                                   20
                                             50:1.
                                                                          5%
                       C 2
                                            / )
                          Eqn. 1:
                                          ,4)% (OD (OD OD))/OD ×100
                                                                           (1)
                          OD, OD, OD_{\mathcal{K}}
                         Measurement of H5Ag-Specific Antibody. 5A -
                                   50 м
                                                                5% C / B 37°
                                  0.05% (v/v) Tween 20 ( B /Tween)
                          В
                                     Β , 100 μ
                                                             0.5% C / B
```

```
C \stackrel{\text{def}}{\longleftarrow} & & B_{-} & \stackrel{\text{def}}{\longrightarrow} & .7 (2010)
                          1.5\% (w/v)
                          (Pharmacia Biotech, A)
     GoldView.
                             <sub>5</sub>⊿y
    Α .
 Statistical Analysis.
1 . . A , Vaccine 2007, 25, 5637.
,A. , . , . , . , . A. , . . , . A. , . . .
                                  , Science
5 . . , Clin. Microbiol. Rev. 2007, 20, 243.
                               , Emerg. Infect.
Dis. 2005, 11, 1515.
               ٦
102, 18141.
17
19 .
```

```
. 7 (2010)
                                                                                       , Vaccine 2008, 26, 532.
   ς . C.
                                                               , B.
                                                                                        , C. A , C. .
        , Vaccine 2001, 19, 3957.
     34
35
37
38
             39
40
41
42
43
             , Dev. Biol. 2003, 115, 31.
      ₹<sub>N</sub>
             44
45 C.
46
47
     LN
48
49
    Natl. Acad. Sci. U.S.A. 2003, 100, 7235.
           Acad. Sci. U.S.A. 2003, 100, 7235.

, Nat. Rev. Immunol. 2008, 8, 713.

, Eur. J. Immunol. 1981, 11, 1012.

, Ann. Hematol. 1998, 76, 231.

, Ann. Hematol. 1985, 161, 1.

, Let y, C. y, ..., Cell 1994, 76, 519.

A J. Immunol. 2001, 16

A J. Immunol. 2005, 62, 36.

, Ann. Hematol. 1998, 76, 231.

, Let y, Seand. J. Immunol. 2005, 62, 36.

, J. Infect. Dis. 1999, 1
50 . .
51
53
54
    . C.
                                                                , J. Immunol. 2001, 166, 7381.
55
56 B. . A
57 A.- .
58
59
60 : 11 · 14
58
                                                                   , J. Infect. Dis. 1999, 180, 579.
                                                                , J. Virol. 1997, 71, 4347.

, J. Virol. 1997, 71, 4347.

, Immunol. Rev. 1997, 159, 95.

, J. Immunol. Methods 2003, 278, 157.
                                                    , , , , ,
```

Received May 28, 2009